Challenges in the Use of the Treat-to-Target Strategy in Atopic Dermatitis in Latin America: A Case Series Review

Publikation: Bidrag til tidsskriftKommentar/debatfagfællebedømt

Standard

Challenges in the Use of the Treat-to-Target Strategy in Atopic Dermatitis in Latin America : A Case Series Review. / Cherrez-Ojeda, Ivan; Robles-Velasco, Karla; Thomsen, Simon Francis; Ramon, German D.; Sánchez, Jorge; Bernstein, Jonathan A.; Hidalgo, Benjamin.

I: Dermatology and Therapy, Bind 13, 2023, s. 661–672.

Publikation: Bidrag til tidsskriftKommentar/debatfagfællebedømt

Harvard

Cherrez-Ojeda, I, Robles-Velasco, K, Thomsen, SF, Ramon, GD, Sánchez, J, Bernstein, JA & Hidalgo, B 2023, 'Challenges in the Use of the Treat-to-Target Strategy in Atopic Dermatitis in Latin America: A Case Series Review', Dermatology and Therapy, bind 13, s. 661–672. https://doi.org/10.1007/s13555-023-00890-7

APA

Cherrez-Ojeda, I., Robles-Velasco, K., Thomsen, S. F., Ramon, G. D., Sánchez, J., Bernstein, J. A., & Hidalgo, B. (2023). Challenges in the Use of the Treat-to-Target Strategy in Atopic Dermatitis in Latin America: A Case Series Review. Dermatology and Therapy, 13, 661–672. https://doi.org/10.1007/s13555-023-00890-7

Vancouver

Cherrez-Ojeda I, Robles-Velasco K, Thomsen SF, Ramon GD, Sánchez J, Bernstein JA o.a. Challenges in the Use of the Treat-to-Target Strategy in Atopic Dermatitis in Latin America: A Case Series Review. Dermatology and Therapy. 2023;13:661–672. https://doi.org/10.1007/s13555-023-00890-7

Author

Cherrez-Ojeda, Ivan ; Robles-Velasco, Karla ; Thomsen, Simon Francis ; Ramon, German D. ; Sánchez, Jorge ; Bernstein, Jonathan A. ; Hidalgo, Benjamin. / Challenges in the Use of the Treat-to-Target Strategy in Atopic Dermatitis in Latin America : A Case Series Review. I: Dermatology and Therapy. 2023 ; Bind 13. s. 661–672.

Bibtex

@article{42ed49f5ee4147938987448c2e5e8598,
title = "Challenges in the Use of the Treat-to-Target Strategy in Atopic Dermatitis in Latin America: A Case Series Review",
abstract = "Introduction: Atopic dermatitis (AD) is a chronic, relapsing–remitting illness. In moderate-to-severe instances, recommendations urge patient-centered systemic therapy. Existing standards lack long-term treatment success requirements. A treat-to-target methodology was proposed for systemic therapy patients that requires global improvements to prompt decisions about treatment. Methods: We conducted an observational study between May 2021 and June 2022 in three Ecuadorian patients with severe AD who were treated with dupilumab to assess the clinical evolution and behavior of the subdomains evaluated by clinimetric tools. Results: Patients A and C satisfied disease-domain response criteria to dupilumab at 12 and 24 weeks, but B did not complete the algorithm objectives. Nonetheless, patient A improved AD severity, itching, bleeding, desquamation, sleep, daily activities, mood, emotions, sexual troubles, clothing, and sports subdomains. Patient B experienced reduced symptomatology, AD aggravation, daily activities impact, and work/study impairment. Patient C improved from severe to mild desquamation, itching, exudate, lichenification, and rough/dry skin. Sleep, shame, and study subdomains improved the most. Conclusion: We provide a new operational construct for analyzing current patient-reported outcome measures (PROMs) and clinician-reported outcome measures (CROMs) based on subdomains to widen our understanding of the state of disease activity and make clinical decisions when the treat-to-target strategy is not attained.",
keywords = "Dupilumab, Patient-reported outcome, Severe atopic dermatitis, Subdomains, Treat-to-target",
author = "Ivan Cherrez-Ojeda and Karla Robles-Velasco and Thomsen, {Simon Francis} and Ramon, {German D.} and Jorge S{\'a}nchez and Bernstein, {Jonathan A.} and Benjamin Hidalgo",
note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",
year = "2023",
doi = "10.1007/s13555-023-00890-7",
language = "English",
volume = "13",
pages = "661–672",
journal = "Dermatology and Therapy",
issn = "2190-9172",
publisher = "Springer Verlag",

}

RIS

TY - JOUR

T1 - Challenges in the Use of the Treat-to-Target Strategy in Atopic Dermatitis in Latin America

T2 - A Case Series Review

AU - Cherrez-Ojeda, Ivan

AU - Robles-Velasco, Karla

AU - Thomsen, Simon Francis

AU - Ramon, German D.

AU - Sánchez, Jorge

AU - Bernstein, Jonathan A.

AU - Hidalgo, Benjamin

N1 - Publisher Copyright: © 2023, The Author(s).

PY - 2023

Y1 - 2023

N2 - Introduction: Atopic dermatitis (AD) is a chronic, relapsing–remitting illness. In moderate-to-severe instances, recommendations urge patient-centered systemic therapy. Existing standards lack long-term treatment success requirements. A treat-to-target methodology was proposed for systemic therapy patients that requires global improvements to prompt decisions about treatment. Methods: We conducted an observational study between May 2021 and June 2022 in three Ecuadorian patients with severe AD who were treated with dupilumab to assess the clinical evolution and behavior of the subdomains evaluated by clinimetric tools. Results: Patients A and C satisfied disease-domain response criteria to dupilumab at 12 and 24 weeks, but B did not complete the algorithm objectives. Nonetheless, patient A improved AD severity, itching, bleeding, desquamation, sleep, daily activities, mood, emotions, sexual troubles, clothing, and sports subdomains. Patient B experienced reduced symptomatology, AD aggravation, daily activities impact, and work/study impairment. Patient C improved from severe to mild desquamation, itching, exudate, lichenification, and rough/dry skin. Sleep, shame, and study subdomains improved the most. Conclusion: We provide a new operational construct for analyzing current patient-reported outcome measures (PROMs) and clinician-reported outcome measures (CROMs) based on subdomains to widen our understanding of the state of disease activity and make clinical decisions when the treat-to-target strategy is not attained.

AB - Introduction: Atopic dermatitis (AD) is a chronic, relapsing–remitting illness. In moderate-to-severe instances, recommendations urge patient-centered systemic therapy. Existing standards lack long-term treatment success requirements. A treat-to-target methodology was proposed for systemic therapy patients that requires global improvements to prompt decisions about treatment. Methods: We conducted an observational study between May 2021 and June 2022 in three Ecuadorian patients with severe AD who were treated with dupilumab to assess the clinical evolution and behavior of the subdomains evaluated by clinimetric tools. Results: Patients A and C satisfied disease-domain response criteria to dupilumab at 12 and 24 weeks, but B did not complete the algorithm objectives. Nonetheless, patient A improved AD severity, itching, bleeding, desquamation, sleep, daily activities, mood, emotions, sexual troubles, clothing, and sports subdomains. Patient B experienced reduced symptomatology, AD aggravation, daily activities impact, and work/study impairment. Patient C improved from severe to mild desquamation, itching, exudate, lichenification, and rough/dry skin. Sleep, shame, and study subdomains improved the most. Conclusion: We provide a new operational construct for analyzing current patient-reported outcome measures (PROMs) and clinician-reported outcome measures (CROMs) based on subdomains to widen our understanding of the state of disease activity and make clinical decisions when the treat-to-target strategy is not attained.

KW - Dupilumab

KW - Patient-reported outcome

KW - Severe atopic dermatitis

KW - Subdomains

KW - Treat-to-target

UR - http://www.scopus.com/inward/record.url?scp=85146999185&partnerID=8YFLogxK

U2 - 10.1007/s13555-023-00890-7

DO - 10.1007/s13555-023-00890-7

M3 - Comment/debate

C2 - 36709473

AN - SCOPUS:85146999185

VL - 13

SP - 661

EP - 672

JO - Dermatology and Therapy

JF - Dermatology and Therapy

SN - 2190-9172

ER -

ID: 337588208